Aspirin downregulates angiotensin type 1 receptor transcription implications in capillary formation from endothelial cells

Journal of Cardiovascular Pharmacology
Sona MitraJawahar L Mehta

Abstract

Aspirin [acetyl salicylic acid (ASA)] inhibits nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and reactive oxygen species generation, a pathway that underlies formation of new capillaries (angiogenesis). Angiotensin II (Ang II) participates in angiogenesis by activating type 1 receptor (AT1R). We examined if ASA would inhibit AT1R transcription, which requires NADPH oxidase, and thereby new capillary formation. Human umbilical vein endothelial cells were cultured in Matrigel and treated with Ang II with and without ASA. Expression of AT1R and NADPH oxidase was measured by quantitative polymerase chain reaction. Ang II in low concentrations induced AT1R messenger RNA and new capillary formation. ASA and its salicylic acid (SA) moiety both suppressed Ang II-mediated AT1R and vascular endothelial growth factor expression and the subsequent new capillary formation. Of note, the AT1R blocker losartan prevented new capillary formation. ASA and SA also suppressed NADPH oxidase (p22, p47, p67, and gp91 messenger RNA) expression. These observations suggest that ASA can inhibit Ang II-induced capillary formation in part via blocking NADPH oxidase and AT1R transcription. Because SA moiety had similar effect as ASA on AT1R exp...Continue Reading

References

Nov 1, 1994·Cardiovascular Research·Y Sun, K T Weber
Aug 2, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D N MullerF C Luft
Jul 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Dayuan LiJawahar L Mehta
Mar 20, 2003·Journal of the American College of Cardiology·Prediman K Shah
Oct 12, 2004·Journal of Cardiovascular Pharmacology·Monika GraningerBernd Jilma
Nov 17, 2004·Molecular and Cellular Biochemistry·Masuko Ushio-Fukai, R Wayne Alexander
Sep 6, 2005·Journal of Atherosclerosis and Thrombosis·Qaisar Khan, Jawahar L Mehta
Sep 21, 2005·Circulation·Rohit KhuranaIan C Zachary
Jun 20, 2006·Cardiovascular Research·Masuko Ushio-Fukai
Jul 28, 2006·American Journal of Physiology. Cell Physiology·Puja K Mehta, Kathy K Griendling
May 22, 2007·Antioxidants & Redox Signaling·Masuko Ushio-Fukai
Jul 20, 2007·Journal of the American Society of Nephrology : JASN·Eisuke SuganumaValentina Kon
Jan 29, 2008·Recent Patents on Cardiovascular Drug Discovery·Dana SkultetyovaJan Skultety
Mar 25, 2009·The Journal of Pathology·Judith C Sluimer, Mat J Daemen
Apr 10, 2009·Current Pharmaceutical Design·Rossella Di StefanoAlberto Balbarini
Jun 6, 2009·Thrombosis and Haemostasis·Andrew C NewbyAnita C Thomas
Feb 4, 2010·Journal of the American Geriatrics Society·Shari R WaldsteinAlan B Zonderman
Jun 5, 2010·Current Hypertension Reports·Leonelo E Bautista, Lina M Vera
Sep 8, 2010·Cardiovascular Research·Elena M V de CavanaghLeón Ferder
Sep 10, 2010·Lipids·Richard D Feinman
Oct 14, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Magomed KhaidakovJawahar L Mehta
Apr 20, 2011·Hypertension·Mazen Kurdi, George W Booz

❮ Previous
Next ❯

Citations

Jul 10, 2014·Cardiovascular Drugs and Therapy·Xianwei WangJawahar L Mehta
May 23, 2015·International Journal of Endocrinology·Norikazu UekiKeizo Kanasaki
Jan 6, 2019·Journal of Cell Communication and Signaling·Gargi MaitySushanta K Banerjee
Mar 4, 2021·European Journal of Pharmacology·Shiyuan XieBin Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.